BioFocus, Ono enter into new drug discovery agreement
BioFocus managing director and Galapagos Services SVP Dr. Chris Newton said, "This project plays to BioFocus historic strengths and the expanding breadth and depth of this partnership is
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.